Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiopurine therapy and semen quality in men with inflammatory bowel disease
NL-OMON23373Recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2017
- Countries
- 1
01
Overview
Open-label, single-arm trial in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change in semen quality during thiopurine exposure. Started Jan 2017; status: recruiting.
02
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON23373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23373.